Laflunimus (Standard)

Overview

Laflunimus (Standard) is the analytical standard of Laflunimus. This product is intended for research and analytical applications. Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 μM for IgM and IgG , respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Others | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > Dihydroorotate Dehydrogenase | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > Prostaglandin Receptor

Product Information

• Catalog No.: HY-101813R
• CAS No.: 147076-36-6
• Molecular Formula: C15H13F3N2O2
• Molecular Weight: 310.27
• Purity: 98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source